Top

Published in:

01-09-2016 | Original Article

Evaluation of ⁶⁸Ga-labeled iNGR peptide with tumor-penetrating motif for microPET imaging of CD13-positive tumor xenografts

Authors: Mingxuan Zhao, Weidong Yang, Mingru Zhang, Guoquan Li, Shengjun Wang, Zhe Wang, Xiaowei Ma, Fei Kang, Jing Wang

Published in: Tumor Biology | Issue 9/2016

Abstract

The aim of the study is to evaluate the efficacy of ⁶⁸Ga-labeled iNGR, containing Asn-Gly-Arg (NGR) homing sequence and CendR (R/KXXR/K) penetrating motif, as a new molecular probe for microPET imaging of CD13-positive xenografts. The synthesized iNGR and NGR peptides were conjugated with DOTA and then labeled with ⁶⁸Ga. ⁶⁸Ga-iNGR and ⁶⁸Ga-NGR were compared in the performance of the in vitro stability, partition coefficient, binding affinity, cell uptake analysis, in vivo microPET imaging, and biodistribution studies in CD13-positive HT-1080 and CD13-negative HT-29 cell lines. The in vitro results revealed that both probes exhibited high radiochemical purity and stability, and no significant difference between two probes was observed in terms of the binding affinity to CD13. In vivo microPET/CT imaging showed that the uptake of ⁶⁸Ga-iNGR in HT-1080 tumor was significantly higher than that of ⁶⁸Ga−NGR. Moreover, tumor ⁶⁸Ga-iNGR uptake could be completely blocked by cold NGR and partially blocked by neutralizing NRP-1 antibody. We concluded that ⁶⁸Ga-iNGR has a higher tumor uptake and better tumor retention than ⁶⁸Ga-NGR through NRP-1, indicating that CendR motif modification is a promising method for improving NGR peptide performance.

Available only for authorised users

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57. doi:10.1038/35025220.CrossRefPubMed

Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol. 2003;55(8):1045–53. doi:10.1211/0022357021819.CrossRefPubMed

Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol. 2001;28(5 Suppl 16):94–104.CrossRefPubMed

Zhang Q, Wang J, Zhang H, Zhao D, Zhang Z, Zhang S. Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer. J Cancer Res Ther. 2015;11(1):223–8. doi:10.4103/0973-1482.138007.CrossRefPubMed

Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102(3):501–8. doi:10.1111/j.1349-7006.2010.01826.x.CrossRefPubMed

Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003;9(4):1503–8.PubMed

Fukasawa K, Fujii H, Saitoh Y, Koizumi K, Aozuka Y, Sekine K, et al. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett. 2006;243(1):135–43. doi:10.1016/j.canlet.2005.11.051.CrossRefPubMed

Su L, Cao J, Jia Y, Zhang X, Fang H, Xu W. Development of synthetic aminopeptidase N/CD13 inhibitors to overcome cancer metastasis and angiogenesis. ACS Med Chem Lett. 2012;3(12):959–64. doi:10.1021/ml3000758.CrossRefPubMedPubMedCentral

Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112(7):2628–35. doi:10.1182/blood-2008-04-150862.CrossRefPubMedPubMedCentral

10.

Chen K, Ma W, Li G, Wang J, Yang W, Yap LP, et al. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Mol Pharm. 2013;10(1):417–27. doi:10.1021/mp3005676.CrossRefPubMed

11.

Ma W, Kang F, Wang Z, Yang W, Li G, Ma X, et al. (99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. Amino Acids. 2013;44(5):1337–45. doi:10.1007/s00726-013-1469-1.CrossRefPubMed

12.

Shao Y, Liang W, Kang F, Yang W, Ma X, Li G, et al. A direct comparison of tumor angiogenesis with (68)Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging. Amino Acids. 2014;46(10):2355–64. doi:10.1007/s00726-014-1788-x.CrossRefPubMed

13.

Zhang J, Lu X, Wan N, Hua Z, Wang Z, Huang H, et al. (68)Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET. Nucl Med Biol. 2014;41(3):268–75. doi:10.1016/j.nucmedbio.2013.12.008.CrossRefPubMed

14.

Mate G, Kertesz I, Enyedi KN, Mezo G, Angyal J, Vasas N, et al. In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer Ga-NOTA-c(NGR). Eur J Pharm Sci. 2015;69C:61–71. doi:10.1016/j.ejps.2015.01.002.CrossRef

15.

Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351–67. doi:10.1007/s00726-005-0289-3.CrossRefPubMed

16.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16(6):510–20. doi:10.1016/j.ccr.2009.10.013.CrossRefPubMedPubMedCentral

17.

Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides. Front Oncol. 2013;3:216. doi:10.3389/fonc.2013.00216.CrossRefPubMedPubMedCentral

18.

Feron O. Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med. 2010;2(34):34ps26. doi:10.1126/scitranslmed.3001174.CrossRefPubMed

19.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, et al. De novo design of a tumor-penetrating peptide. Cancer Res. 2013;73(2):804–12. doi:10.1158/0008-5472.CAN-12-1668.CrossRefPubMed

20.

Ye Y, Zhu L, Ma Y, Niu G, Chen X. Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett. 2011;21(4):1146–50. doi:10.1016/j.bmcl.2010.12.112.CrossRefPubMed

21.

Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res. 2007;13(12):3470–81. doi:10.1158/1078-0432.CCR-07-0264.CrossRefPubMed

22.

Liu S, Jia B, Qiao R, Yang Z, Yu Z, Liu Z, et al. A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation, characterization and in vivo application. Mol Pharm. 2009;6(4):1074–82. doi:10.1021/mp900143a.CrossRefPubMed

23.

Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6(5):350–9. doi:10.1016/j.mibio.2004.06.004.CrossRefPubMed

24.

Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008;51(24):7980–90. doi:10.1021/jm801134k.CrossRefPubMedPubMedCentral

25.

Yang Y, Xie X, Yang Y, Zhang H, Mei X. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy. J Pharm Sci. 2015;104(4):1328–39. doi:10.1002/jps.24333.CrossRefPubMed

26.

Wu H, Chen H, Pan D, Ma Y, Liang S, Wan Y, et al. Imaging integrin alphavbeta 3 and NRP-1 positive gliomas with a novel fluorine-18 labeled RGD-ATWLPPR heterodimeric peptide probe. Mol Imaging Biol. 2014;16(6):781–92. doi:10.1007/s11307-014-0761-0.CrossRefPubMed

27.

Menichetti L, Kusmic C, Panetta D, Arosio D, Petroni D, Matteucci M, et al. MicroPET/CT imaging of alphavbeta(3) integrin via a novel (6)(8)Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40(8):1265–74. doi:10.1007/s00259-013-2432-9.CrossRefPubMed

28.

Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008;111(5):2674–80. doi:10.1182/blood-2007-08-110205.CrossRefPubMedPubMedCentral

29.

Salikhova A, Wang L, Lanahan AA, Liu M, Simons M, Leenders WP, et al. Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res. 2008;103(6):e71–9. doi:10.1161/CIRCRESAHA.108.183327.CrossRefPubMedPubMedCentral

30.

Yang Z, Xiang B, Dong D, Wang Z, Li J, Qi X. Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy. Curr Gene Ther. 2014;14(4):289–99.CrossRefPubMed

Title: Evaluation of 68Ga-labeled iNGR peptide with tumor-penetrating motif for microPET imaging of CD13-positive tumor xenografts
Authors: Mingxuan Zhao
Weidong Yang
Mingru Zhang
Guoquan Li
Shengjun Wang
Zhe Wang
Xiaowei Ma
Fei Kang
Jing Wang
Publication date: 01-09-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5068-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway

DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells

miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1

Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection

Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer

The dual regulatory role of miR-204 in cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer